“…Well-known challenges in the differential diagnosis of MDS, 14 and the prospects that new molecular data also pave the way to improve risk stratification and treatment strategies 15 corroborate the importance of studies addressing the molecular pathogenesis of myeloid malignancies and in particular of MDS.…”